Skye Bioscience is a biopharmaceutical company studying the pharmaceutical potential of cannabinoids through the development of its proprietary cannabinoid-derived molecules to treat diseases with significant unmet needs. The company’s lead molecule, which is in preclinical studies, may serve as a new class of therapy to lower IOP in patients with glaucoma or elevated IOP.

Skye is currently advancing manufacturing and formulation work on its lead molecule THCVHS in preparation for entering the clinic later this year. The company anticipates releasing top-line data from its first-in-humans phase 1 study of THCVHS for the treatment of glaucoma in early 2022.